VRTXON

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Namn VRTXON

Rank No.3624

Marknadsvärde $0.00

Marknadsvärde efter full utspädning $0.00

Marknadsandel %

Handelsvolym/marknadsvärde (24h) 18,132,562.15%

Cirkulationsutbud 4.00949604

Maxutbud 0

Totalt utbud 4.00949604

Cirkulationshastighet %

Utgivningsdatum --

Det pris till vilket tillgången först emitterades --

Högsta någonsin 466.35223147502205, 2026-03-26

Lägsta pris 414.92035330237934, 2026-05-05

Offentlig blockkedja VRTXON

Introduktion Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Sektor

Sociala medier

• Twitter

• Officiell webbplats
• Blockutforskare

Analys av fondflöden

etfindex:mc_etfindex_source Ansvarsfriskrivning: Data tillhandahålls av cmc och ska inte betraktas som investeringsrådgivning.